CORRECTION FROM SOURCE: Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2022
Vaso Corporation reported its annual financial results for 2022, achieving a record annual revenue of $80.0 million, a 5.9% increase from 2021. Annual net income rose to $11.9 million, up 95.7% year-over-year. The company highlighted strong performance in its professional sales service segment and improved operating results in the IT segment. However, the fourth-quarter revenue decreased by 4.2% compared to the prior year, attributed to lower revenues across all segments. Vaso ended the year with $20.3 million in cash and short-term investments and a significant increase in deferred revenue to $30.8 million.
- Annual revenue increased by 5.9% to $80.0 million.
- Net income rose to $11.9 million, a 95.7% increase year-over-year.
- Operating income for the year increased by 149.5% to $7.0 million.
- Deferred revenue increased to $30.8 million, a historic high.
- Fourth-quarter revenue decreased by 4.2% to $23.5 million.
- IT segment revenue fell by 6.6% to $40.1 million for the year.
- Equipment segment revenue down 20.1% due to reduced sales in China.
The Company Announces Record Annual Revenue and Profit
PLAINVIEW, NY / ACCESSWIRE / March 29, 2023 / Vaso Corporation ("Vaso") (OTCQB:VASO) today announced its operating results for the three months and year ended December 31, 2022.
"The Company recorded annual revenue of
"Our balance sheet remains strong, with
"With a healthy financial position and a diversified business portfolio, management is optimistic about the Company's performance going forward. Our IT segment has improved operating efficiency as it's recovering from the impact of the COVID-19 pandemic; our professional sales service segment continues to outperform expectations and has expanded the scope of its partnership with GE HealthCare; and our equipment segment is starting to evolve from a pure product play to a more product-based service business. We would not be able to accomplish all these without our employees' dedication and professionalism. On behalf of the board of directors, I want to thank them as well as our shareholders for their continued support," concluded Dr. Ma.
Financial Results for Three Months Ended December 31, 2022
For the three months ended December 31, 2022, revenue decreased by
Gross profit for the fourth quarter of 2022 decreased by
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2022 increased by
Net income for the three months ended December 31, 2022 was
Financial Results for Year Ended December 31, 2022
For the year ended December 31, 2022, revenue increased by
Gross profit for the year ended December 31, 2022 increased by
SG&A expenses for the year ended December 31, 2022 increased by
For the year ended December 31, 2022, the Company had net income of
Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, and share-based compensation) was
Net cash provided from operating activities in 2022 was
Deferred revenue increased to
About Vaso
Vaso Corporation is a diversified medical technology company with several distinctive but related specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for medical equipment; and design, manufacture and sale of proprietary medical devices.
The Company operates through three wholly owned subsidiaries:
- VasoTechnology, Inc. provides network and IT services through two business units: NetWolves Network Services LLC, a managed network services provider with an extensive, proprietary service platform to a broad base of customers; and VasoHealthcare IT Corp., a national value added reseller of Radiology Information System ("RIS"), Picture Archiving and Communication System ("PACS"), and other software solutions from various vendors as well as related services, including implementation, management and support.
- Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE HealthCare diagnostic imaging and ultrasound products in certain market segments in the USA.
- VasoMedical, Inc. manages and coordinates the design, manufacture and sales of proprietary medical equipment and software, as well as operates the Company's overseas assets including China-based subsidiaries.
Additional information is available on the Company's website at www.vasocorporation.com.
Summarized Financial Information
FOR THE THREE MONTHS ENDED | FOR THE YEAR ENDED | |||||||||||||||
STATEMENTS OF OPERATIONS | December 31, 2022 | December 31, 2021 | December 31, 2022 | December 31, 2021 | ||||||||||||
(In thousands) | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Revenue | $ | 23,470 | $ | 24,500 | $ | 80,017 | $ | 75,579 | ||||||||
Gross profit | 14,840 | 15,674 | 48,481 | 43,133 | ||||||||||||
Operating income | 3,398 | 3,443 | 7,033 | 2,819 | ||||||||||||
Other income (expense), net | 41 | (67 | ) | 97 | 3,432 | |||||||||||
Income before taxes | 3,439 | 3,376 | 7,130 | 6,251 | ||||||||||||
Income tax benefit (expense) | 4,785 | (64 | ) | 4,743 | (151 | ) | ||||||||||
Net income | 8,224 | 3,312 | 11,873 | 6,100 | ||||||||||||
Income tax (benefit) expense | (4,785 | ) | 64 | (4,743 | ) | 151 | ||||||||||
Interest (income) expense, net | (75 | ) | 40 | (85 | ) | 301 | ||||||||||
Depreciation and amortization | 347 | 2,092 | 1,923 | 3,840 | ||||||||||||
Non-cash stock-based compensation | 13 | 6 | 35 | 31 | ||||||||||||
Adjusted EBITDA* | $ | 3,724 | $ | 5,514 | $ | 9,003 | $ | 10,423 | ||||||||
BALANCE SHEETS | December 31, 2022 | December 31, 2021 | ||||||||||||||
(In thousands) | ||||||||||||||||
Total current assets | $ | 42,000 | $ | 27,803 | ||||||||||||
Total assets | $ | 72,655 | $ | 52,361 | ||||||||||||
Total current liabilities | $ | 31,708 | $ | 31,000 | ||||||||||||
Total stockholders' equity | $ | 22,875 | $ | 11,310 | ||||||||||||
*Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization and non-cash stock-based compensation. |
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "optimistic", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the US economy and the continued impact of the COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
SOURCE: Vaso Corporation
View source version on accesswire.com:
https://www.accesswire.com/746443/CORRECTION-FROM-SOURCE-Vaso-Corporation-Announces-Financial-Results-for-Fourth-Quarter-and-Full-Year-of-2022
FAQ
What was Vaso Corporation's annual revenue for 2022?
How much did Vaso's net income increase in 2022?
What was the growth rate of Vaso's revenue in the fourth quarter of 2022?
What are the key segments contributing to Vaso's growth?